MedPath
HSA Approval

Daxotel Concentrate for Solution for Infusion 20mg/ml

SIN15109P

Daxotel Concentrate for Solution for Infusion 20mg/ml

Daxotel Concentrate for Solution for Infusion 20mg/ml

October 26, 2016

FRESENIUS KABI (SINGAPORE) PTE LTD

FRESENIUS KABI (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantFRESENIUS KABI (SINGAPORE) PTE LTD
Licence HolderFRESENIUS KABI (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION, CONCENTRATE

INTRAVENOUS

Medical Information

L01CD02

docetaxel

Manufacturer Information

FRESENIUS KABI (SINGAPORE) PTE LTD

Fresenius Kabi Oncology Limited

Active Ingredients

Docetaxel Anhydrous

20.0mg/ml

Docetaxel

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Daxotel Concentrate for Solution for Infusion 20mg/ml - HSA Approval | MedPath